Torabi SJ, et al. - Because Ewing sarcoma of the head and neck (ESHN) is a rare malignancy for which there is limited data, researchers carried out multivariate Cox regression and univariate Kaplan-Meier survival analyses to study anatomic distribution of ESHN, demographic features, and multi-modal therapy as potential determinants in the overall survival (OS) of patients with ESHN. Using the National Cancer Database from 2004–2016, 284 individuals with ESHN eligible for demographic analysis and 223 for survival analysis were identified. According to findings, OS predictors in ESHN patients included age < 18 years and non-metastatic disease at the time of diagnosis. Tumor site of origin (osseous vs extraosseous primary) or the addition of local therapy (either surgery, radiotherapy, or both) to chemotherapy did not affect the OS. Findings indicate that chemotherapy is the primary modality for the treatment of ESHN, while further study of this rare malignancy is needed to discern the usefulness of combined systemic and local therapy.